FDA Inspection 1230050 — Endo USA, Inc.
The FDA completed an inspection of Endo USA, Inc. on Aug 15, 2024 in Malvern, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 15, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Malvern, PA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)